BeOne Medicines strikes voluntary deal with US government to widen access to its cancer drugs

BeOne Medicines has entered a voluntary agreement with the US government aimed at broadening American patients’ access to its oncology medicines while building out its domestic manufacturing base and scaling up its capacity to produce drugs. The company frames the deal as an extension of its existing focus on patient access and investment in research and innovation.

John Oyler, BeOne’s co-founder, chairman and chief executive, said the company holds that every cancer patient should have access to innovative therapies. He credited the Trump administration for pushing solutions that widen access and support scientific progress for patients in the US, and said the agreement reflects the company’s goal of reaching more patients as it grows its US investment in research, development and manufacturing to bring cancer treatments to patients worldwide.

The agreement ties into BeOne’s participation in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model, along with a commitment to price future FDA-approved products in line with other major developed markets.

On the manufacturing side, BeOne says its ongoing US investments are meant to strengthen supply reliability and give it more flexibility in production, supporting broader patient access to its medicines. As part of the deal, the company secured an onshoring agreement with the US government that exempts it from Section 232 pharmaceutical tariffs, in recognition of its substantial and continuing investment in domestic manufacturing.

That builds on a $300 million onshoring investment BeOne announced recently for its flagship clinical and commercial-stage manufacturing and R&D site in Hopewell, New Jersey, which brings its total US manufacturing investment past $1 billion. The expansion will add small-molecule manufacturing capacity, create roughly 120 full-time positions, and boost the company’s ability to manufacture medicines domestically while advancing its oncology pipeline of more than 35 clinical- and commercial-stage programs.

The US plays a central role in BeOne’s scientific, clinical and manufacturing work. The company employs over 2,000 people in the US as part of a global workforce topping 12,000 across six continents. It generated close to $2 billion in direct US economic impact in 2025 and put $1 billion into US research and development that year. BeOne is also running 93 clinical trials across roughly 1,100 sites in 45 states and one US territory, with support from more than 650 investigators.

---

---

Related Topics and Keywords

beone, beone medicines, Cancer, cancer drugs, FDA Approval, US FDA